Posted by Michael Wonder on 06 May 2021
Health Canada issues Notice of Compliance for Bausch Health's Bryhali
5 May 2021 - Bausch Health Canada today announced that Health Canada has approved the use of Bryhali (halobetasol propionate 0.01% w/w lotion), a high to super-high potency topical corticosteroid indicated for corticosteroid responsive dermatoses and the topical treatment of plaque psoriasis.
Bryhali will be available in Canada in the coming months.
